CASE STUDIES

DK- Improved control/ Controlling Metabolic

- Ms DK

- Age 34

- Iwi Trust worker /Treaty claims

- In May 2024 – presented with poorly controlled diabetes (Hba1c 103)

- Hypertensive crises

- At discharge

- - Self funded Empagliflozin

- GLP-1

- Metformin

- Self funded Libre 2

AGP Report

17 November 2024 - 30 November 2024 (14 Days)

LibreView

GLUCOSE STATISTICS AND TARGETS

17 November 2024 - 30 November 2024	14 Days
Time Sensor Active:	**30%**

| Ranges And Targets For	Type 1 or Type 2 Diabetes
Glucose Ranges	**Targets** % of Readings (Time/Day)
Target Range 3.9-10.0 mmol/L	Greater than 70% (16h 48min)
Below 3.9 mmol/L	Less than 4% (58min)
Below 3.0 mmol/L	Less than 1% (14min)
Above 10.0 mmol/L	Less than 25% (6h)
Above 13.9 mmol/L	Less than 5% (1h 12min)
Each 5% increase in time in range (3.9-10.0 mmol/L) is clinically beneficial.	

Average Glucose	**7.9** mmol/L
Glucose Management Indicator (GMI)	**-**
Glucose Variability	**19.0%**

Defined as percent coefficient of variation (%CV); target ≤36%

TIME IN RANGES

Very High >13.9 mmol/L	**0%**	(0min)
High 10.1 - 13.9 mmol/L	**10%**	(2h 24min)
Target Range 3.9 - 10.0 mmol/L	**90%**	(21h 36min)
Low 3.0 - 3.8 mmol/L	**0%**	(0min)
Very Low <3.0 mmol/L	**0%**	(0min)

13.9
10.0
3.9
3.0

Changes post CGM

Parameter	May 2024	November 2024
HbA1C(mmol/mol)	86	54
Weight(Kg)	144	133.8
Total Cholesterol (mmol)	7.2	5.5

Mrs MK

- 58 year old Indian woman
- Initially referred by her GP to start insulin-Hba1c 103

  - Previously on Galvumet 50/1000mg po bd

  - Gliclazide 80mg po bd

- Seen by Diabetes Nurse specialist
- Noted fasting sugars 6-8mmol post prandial 10-13mmol
- Empagliflozin started 10mg
- Gliclazide to max dose 160mg/day
- Initial Hba1c 103-> 77 by October 2024
- Trial of Libre commenced in Late November 2024

Type 2
Other medical problems include Diabetic Proliferative retinopathy

Neuropathic symptoms with reduction of protective sensation.

Treated Hypertension: Blood pressure 118/76 mmHg
- Raised BMI: Weight 74.1 kg height 156.5 cm BMI 30
- Hypothyroidism
- History of treated breast cancer

AGP Report

LibreView

GLUCOSE STATISTICS AND TARGETS

19 November 2024 - 2 December 2024	14 Days
Time Sensor Active:	**97%**

Ranges And Targets For	Type 1 or Type 2 Diabetes
Glucose Ranges	**Targets** % of Readings (Time/Day)
Target Range 3.9-10.0 mmol/L	Greater than 70% (16h 48min)
Below 3.9 mmol/L	Less than 4% (58min)
Below 3.0 mmol/L	Less than 1% (14min)
Above 10.0 mmol/L	Less than 25% (6h)
Above 13.9 mmol/L	Less than 5% (1h 12min)

Each 5% increase in time in range (3.9-10.0 mmol/L) is clinically beneficial.

Average Glucose	**8.6** mmol/L
Glucose Management Indicator (GMI)	**7.0% or 53 mmol/mol**
Glucose Variability	**30.5%**

Defined as percent coefficient of variation (%CV); target ≤36%

TIME IN RANGES

Very High >13.9 mmol/L	**3%**	(43min)
High 10.1 - 13.9 mmol/L	**22%**	(5h 17min)
Target Range 3.9 - 10.0 mmol/L	**74%**	(17h 46min)
Low 3.0 - 3.8 mmol/L	**1%**	(14min)
Very Low <3.0 mmol/L	**0%**	(0min)

13.9
10.0
3.9
3.0

Review of Libre

- Some overnight lows , Gliclazide

- Reduced to 80mg overnight

- Can potentially modify breakfast

- Increase Empag to 25mg to smooth out post Breakfast rise

Mr BZ

- Type 2 diabetes
- Age 35
- End Stage Renal impairment
- Peritoneal dialysis
- Using Libre
- Limitations on Usefulness by MARD
- Seen in Clinic
- Medications
- Lantus
- Metformin

Xu Bingyu

DOB: 26/12/1985

MRN: _____

DEVICE: FreeStyle LibreLink

Waitemata DHB Diabetes Service

PHONE: 094861491

Generated: 18/01/2025

AGP Report

LibreView

15 March 2024 - 28 March 2024 (14 Days)

GLUCOSE STATISTICS AND TARGETS

15 March 2024 - 28 March 2024	**14 Days**
Time Sensor Active:	**97%**

Ranges And Targets For	Type 1 or Type 2 Diabetes
Glucose Ranges	**Targets** % of Readings (Time/Day)
Target Range 3.9-10.0 mmol/L	Greater than 70% (16h 48min)
Below 3.9 mmol/L	Less than 4% (58min)
Below 3.0 mmol/L	Less than 1% (14min)
Above 10.0 mmol/L	Less than 25% (6h)
Above 13.9 mmol/L	Less than 5% (1h 12min)
Each 5% increase in time in range (3.9-10.0 mmol/L) is clinically beneficial.	

Average Glucose	**8.8** mmol/L
Glucose Management Indicator (GMI)	**7.1% or 54 mmol/mol**
Glucose Variability	**25.8%**

Defined as percent coefficient of variation (%CV); target ≤36%

TIME IN RANGES

Very High >13.9 mmol/L   **2%** (29min)

13.9

High 10.1 - 13.9 mmol/L   **28%** (6h 43min)

10.0

Target Range 3.9 - 10.0 mmol/L   **70%** (16h 48min)

3.9
3.0

Low 3.0 - 3.8 mmol/L   **0%** (0min)

Very Low <3.0 mmol/L   **0%** (0min)

Changes in clinic

- Added Vildagliptin

- Reduce dose of Lantus

Case IV TL

- 58 year old woman
- Diagnosed with diabetes in 2010
- Refused to accept diagnosis
- Years of Poorly controlled Diabetes
- Late 2023- presented with a CVA and Quadrantanopia
- Hba1c 126
- Started Empagliflozin- Euglycemic DKA
- Started Lantus